KRAS and pancreatic neoplasm: There is also a report that the time to recurrence did not differ between patients receiving and not receiving an adjuvant therapy [32], and another report showed that dMMR pancreatic cancers were poorly differentiated and wild-type KRAS was frequently expressed in them [27].